SEC Filing Summary: Renovaro Biosciences Inc. (8-K)
Business Context and Reporting Period
This Form 8-K Current Report was filed by Renovaro Biosciences Inc. (RENB) on October 10, 2023, covering events occurring on October 4, 2023. The filing addresses corporate governance changes, specifically the expansion of the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and does not contain financial performance data.
Material Changes
- Board Expansion: The Board of Directors increased its size to ten members.
- New Appointments: Leni Boeren and Ruud Hendriks were appointed as independent directors effective October 4, 2023, to fill vacancies.
- Term Duration: The new directors will serve until the 2024 Annual Meeting of Stockholders or until their successors are elected.
- Compensation: New directors will receive compensation consistent with the Company's existing director compensation program disclosed in the 2023 proxy statement.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, operational outlook, or specific risk factors. It confirms there are no undisclosed arrangements or transactions between the new directors and the Company requiring disclosure under Item 404(a) of Regulation S-K. A press release regarding these appointments was issued on October 10, 2023, and is attached as Exhibit 99.1.
Investor Verification Checklist
- Verify the biographies and qualifications of new directors Leni Boeren and Ruud Hendriks.
- Review the definitive proxy statement for the 2023 annual meeting to confirm the specific compensation structure for independent directors.
- Confirm the total number of board vacancies filled and the remaining composition of the Board.
- Check for any subsequent filings regarding the 2024 Annual Meeting of Stockholders.